Connection

Giuseppe Curigliano to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Giuseppe Curigliano has written about Dose-Response Relationship, Drug.
Giuseppe Curigliano
Connection Strength
0.024
Dose-Response Relationship, Drug
  1. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019 03; 20(3):371-382.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.